A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway |
Kim, Tae-Ho
(College of Pharmacy, Ajou University)
Lee, Dong Gil (College of Pharmacy, Ajou University) Kim, Young-Ae (College of Pharmacy, Ajou University) Lee, Byung Ho (Korea Research Institute of Chemical Technology) Yi, Kyu Yang (Korea Research Institute of Chemical Technology) Jung, Yi-Sook (College of Pharmacy, Ajou University) |
1 | Lee, K., Yim, J. H., Lee, H. K. and Pyo, S. (2016) Inhibition of VCAM-1 expression on mouse vascular smooth muscle cells by lobastin via downregulation of p38, ERK 1/2 and signaling pathways. Arch. Pharm. Res. 39, 83-93. DOI |
2 | Lee, N. Y., Rieckmann, P. and Kang, Y. S. (2012) The changes of P-glycoprotein activity by interferon- and tumor necrosis factor- in primary and immortalized human brain microvascular endothelial cells. Biomol. Ther. (Seoul) 20, 293-298. DOI |
3 | Liang, Q., Yu, F., Cui, X., Duan, J., Wu, Q., Nagarkatti, P. and Fan, D. (2013) Sparstolonin B suppresses lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells. Arch. Pharm. Res. 36, 890-896. DOI |
4 | Loirand, G., Rolli-Derkinderen, M. and Pacaud, P. (2008) Urotensin II and atherosclerosis. Peptides 29, 778-782. DOI |
5 | Louis, S. F. and Zahradka, P. (2010) Vascular smooth muscle cell motility: From migration to invasion. Exp. Clin. Cardiol. 15, e75-e85. |
6 | Ou, Y., Li, Q., Wang, J., Li, K. and Zhou, S. (2014) Antitumor and apoptosis induction effects of paeonol on mice bearing EMT6 breast carcinoma. Biomol. Ther. (Seoul) 22, 341-346. DOI |
7 | Park, S. L., Lee, B. K., Kim, Y. A., Lee, B. H. and Jung, Y. S. (2013) Inhibitory effect of an urotensin II receptor antagonist on proinflammatory activation induced by urotensin II in human vascular endothelial cells. Biomol. Ther. (Seoul) 21, 277-283. DOI |
8 | Pendyala, S., Usatyuk, P. V., Gorshkova, I. A., Garcia, J. G. and Natarajan, V. (2009) Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid. Redox Signal. 11, 841-860. DOI |
9 | Rudijanto, A. (2007) The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med. Indones. 39, 86-93. |
10 | Rakowski, E., Hassan, G. S., Dhanak, D., Ohlstein, E. H., Douglas, S. A. and Giaid, A. (2005) A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J. Mol. Cell. Cardiol. 39, 785-791. DOI |
11 | Sauzeau, V., Le Mellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P. and Loirand, G. (2001) Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res. 88, 1102-1104. DOI |
12 | Sindermann, J. R., Smith, J., Kobbert, C., Plenz, G., Skaletz-Rorowski, A., Solomon, J. L., Fan, L. and March, K. L. (2002) Direct evidence for the importance of p130 in injury response and arterial remodeling following carotid artery ligation. Cardiovasc. Res. 54, 676-683. DOI |
13 | Suguro, T., Watanabe, T., Ban, Y., Kodate, S., Misaki, A., Hirano, T., Miyazaki, A. and Adachi, M. (2007) Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am. J. Hypertens. 20, 211-217. DOI |
14 | Tsoukas, P., Kane, E. and Giaid, A. (2011) Potential clinical implications of the urotensin II receptor antagonists. Front. Pharmacol. 2, 38. |
15 | Watanabe, T., Arita, S., Shiraishi, Y., Suguro, T., Sakai, T., Hongo, S. and Miyazaki, A. (2009) Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr. Med. Chem. 16, 550-563. DOI |
16 | Djordjevic, T., BelAiba, R. S., Bonello, S., Pfeilschifter, J., Hess, J. and Gorlach, A. (2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 25, 519-525. DOI |
17 | Ames, R. S., Sarau, H. M., Chambers, J. K., Willette, R. N., Aiyar, N. V., Romanic, A. M., Louden, C. S., Foley, J. J., Sauermelch, C. F., Coatney, R. W., Ao, Z., Disa, J., Holmes, S. D., Stadel, J. M., Martin, J. D., Liu, W. S., Glover, G. I., Wilson, S., McNulty, D. E., Ellis, C. E., Elshourbagy, N. A., Shabon, U., Trill, J. J., Hay, D. W., Ohlstein, E. H., Bergsma, D. J. and Douglas, S. A. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401, 282-286. DOI |
18 | Behm, D. J., Aiyar, N. V., Olzinski, A. R., McAtee, J. J., Hilfiker, M. A., Dodson, J. W., Dowdell, S. E., Wang, G. Z., Goodman, K. B., Sehon, C. A., Harpel, M. R., Willette, R. N., Neeb, M. J., Leach, C. A. and Douglas, S. A. (2010) GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo. Br. J. Pharmacol. 161, 207-228. DOI |
19 | Behm, D. J., McAtee, J. J., Dodson, J. W., Neeb, M. J., Fries, H. E., Evans, C. A., Hernandez, R. R., Hoffman, K. D., Harrison, S. M., Lai, J. M., Wu, C., Aiyar, N. V., Ohlstein, E. H. and Douglas, S. A. (2008) Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br. J. Pharmacol. 155, 374-386. |
20 | Chen, Y. L., Liu, J. C., Loh, S. H., Chen, C. H., Hong, C. Y., Chen, J. J. and Cheng, T. H. (2008) Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur. J. Pharmacol. 593, 24-29. DOI |
21 | Duran-Prado, M., Morell, M., Delgado-Maroto, V., Castano, J. P., Aneiros-Fernandez, J., de Lecea, L., Culler, M. D., Hernandez-Cortes, P., O'Valle, F. and Delgado, M. (2013) Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation. Circ. Res. 112, 1444-1455. DOI |
22 | Ferguson, D., Koo, J. W., Feng, J., Heller, E., Rabkin, J., Heshmati, M., Renthal, W., Neve, R., Liu, X., Shao, N., Sartorelli, V., Shen, L. and Nestler, E. J. (2013) Essential role of SIRT1 signaling in the nucleus accumbens in cocaine and morphine action. J. Neurosci. 33, 16088-16098. DOI |
23 | Heringlake, M., Kox, T., Uzun, O., Will, B., Bahlmann, L., Klaus, S., Eleftheriadis, S., Armbruster, F. P., Franz, N. and Kraatz, E. (2004) The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul. Pept. 121, 129-136. DOI |
24 | Lee, B. K. and Jung, Y. S. (2012) The exchanger-1 inhibitor cariporide prevents glutamate-induced necrotic neuronal death by inhibiting mitochondrial overload. J. Neurosci. Res. 90, 860-869. DOI |
25 | Huang, J., Zhang, J., Pathak, A., Li, J. and Stouffer, G. A. (2011) Perivascular delivery of blebbistatin reduces neointimal hyperplasia after carotid injury in the mouse. J. Pharmacol. Exp. Ther. 336, 116-126. DOI |